Rockefeller Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.1M | Buy |
1,164,394
+26,300
| +2% | +$567K | 0.06% | 319 |
|
|
2025
Q1 | $18.9M | Sell |
1,138,094
-25,361
| -2% | -$421K | 0.05% | 380 |
|
|
2024
Q4 | $21.3M | Buy |
1,163,455
+23,521
| +2% | +$432K | 0.06% | 331 |
|
|
2024
Q3 | $17.5M | Buy |
1,139,934
+185,684
| +19% | +$2.86M | 0.05% | 383 |
|
|
2024
Q2 | $15.5M | Buy |
954,250
+165,798
| +21% | +$2.69M | 0.04% | 391 |
|
|
2024
Q1 | $14.6M | Buy |
788,452
+232,115
| +42% | +$4.29M | 0.04% | 407 |
|
|
2023
Q4 | $17.4M | Buy |
556,337
+51,164
| +10% | +$1.6M | 0.06% | 316 |
|
|
2023
Q3 | $10.5M | Buy |
505,173
+100,884
| +25% | +$2.1M | 0.04% | 404 |
|
|
2023
Q2 | $9.68M | Sell |
404,289
-76,591
| -16% | -$1.83M | 0.04% | 437 |
|
|
2023
Q1 | $9.05M | Buy |
480,880
+17,239
| +4% | +$324K | 0.04% | 439 |
|
|
2022
Q4 | $7.38M | Buy |
463,641
+4,811
| +1% | +$76.6K | 0.04% | 441 |
|
|
2022
Q3 | $7.51M | Buy |
458,830
+23,595
| +5% | +$386K | 0.04% | 438 |
|
|
2022
Q2 | $6.13M | Buy |
435,235
+117,500
| +37% | +$1.66M | 0.03% | 459 |
|
|
2022
Q1 | $7.69M | Buy |
317,735
+15,239
| +5% | +$369K | 0.04% | 436 |
|
|
2021
Q4 | $7.06M | Buy |
302,496
+21,268
| +8% | +$496K | 0.03% | 441 |
|
|
2021
Q3 | $4.67M | Buy |
281,228
+49,644
| +21% | +$825K | 0.02% | 498 |
|
|
2021
Q2 | $5.65M | Buy |
231,584
+226,222
| +4,219% | +$5.52M | 0.03% | 422 |
|
|
2021
Q1 | $138K | Buy |
5,362
+2,494
| +87% | +$64.2K | ﹤0.01% | 1467 |
|
|
2020
Q4 | $152K | Sell |
2,868
-3,094
| -52% | -$164K | ﹤0.01% | 1279 |
|
|
2020
Q3 | $245K | Buy |
5,962
+5,945
| +34,971% | +$244K | ﹤0.01% | 972 |
|
|
2020
Q2 | $1K | Buy |
+17
| New | +$1K | ﹤0.01% | 2407 |
|
|
2019
Q2 | – | Sell |
-68
| Closed | -$2K | – | 1630 |
|
|
2019
Q1 | $2K | Buy |
+68
| New | +$2K | ﹤0.01% | 1762 |
|